HOUSTON--(BUSINESS WIRE)--Oncolin Therapeutics, Inc. (OTCBB:OCOL) is pleased to announce that it has signed a sponsored research agreement with The University of Texas M. D. Anderson Cancer Center (UTMDACC) in Houston, Texas to support work in the laboratory of Prof. Waldemar Priebe. This new sponsored research will focus on the development of a new novel class of compounds that inhibit glycolysis, the metabolic pathway essential to the survival of many human tumors. The company will have a right to an exclusive license to any new patents derived from this research as the company expands its support of Dr. Priebe’s drug discovery and development efforts. This sponsored research will initially focus on evaluation of the selected lead compounds with the goal of identifying a superior inhibitor of glycolysis that potently blocks tumor growth.
